Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Total article views   HTML views PDF downloads Totals
6,882 Dovepress* 6,882+ 2,721 9,603
Totals 6,882 2,721 9,603
*Since 8 February 2008
+Since July 2016

View citations on Google Scholar